BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Press Releases

  Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

  March 30, 2026

   · 

  6 min read
• Press Releases

  Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform

  March 30, 2026

   · 

  3 min read
• Press Releases

  AP Biosciences and Tasly Finalize Amended Collaboration Agreement to Support Global Out-Licensing of AP505 (B1962)

  March 30, 2026

   · 

  3 min read
• Press Releases

  HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors

  March 30, 2026

   · 

  2 min read
• Press Releases

  Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

  March 30, 2026

   · 

  7 min read
• Press Releases

  4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union

  March 30, 2026

   · 

  4 min read
• Press Releases

  FDA Approves High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy, Reflecting Progress Made Possible Through Decades of MDA Supported Research

  March 30, 2026

   · 

  4 min read
• Press Releases

  Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings

  March 30, 2026

   · 

  5 min read
• 

  Approvals

  Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug

  The FDA rejected the high-dose regimen of Spinraza in September last year due to manufacturing concerns.

  March 30, 2026

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Cardiovascular disease

  Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout

  While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.

  March 30, 2026

   · 

  2 min read

   · 

  Annalee Armstrong